James McLaughlin, MD
Internal Medicine · Montgomery, ALNPI 1568453124
Payments from drug & device makers
Across 147 payments — averaging $17.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$498
- AstraZeneca$418
- GSK$289
- Pfizer$148
- Boehringer Ingelheim$137
- Lilly USA, LLC$134
- plus $964 from 29 others
What the payments were for
- Food & beverage$2,51797%
- Education$120%
- Gifts$592%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 31 | $498 |
| AstraZeneca | 24 | $418 |
| GSK | 15 | $289 |
| Pfizer | 10 | $148 |
| Boehringer Ingelheim | 8 | $137 |
| Lilly USA, LLC | 9 | $134 |
| Amgen(2 entities) | 5 | $88 |
| Abbott | 4 | $74 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $63 |
| Mannkind Corporation | 1 | $59 |
| Neurocrine Biosciences, Inc. | 2 | $54 |
| Bayer | 3 | $52 |
| Beckman Coulter, Inc. | 1 | $50 |
| Phathom Pharmaceuticals, Inc. | 3 | $50 |
| Sanofi-aventis U.S. LLC | 3 | $47 |
| AbbVie | 3 | $44 |
| Dexcom, Inc. | 2 | $32 |
| Exact Sciences | 2 | $32 |
| Johnson & Johnson | 2 | $30 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Radius Health, Inc. | 1 | $23 |
| Amarin Pharma, Inc. | 1 | $22 |
| IBSA Pharma Inc. | 1 | $21 |
| Astellas Pharma US Inc | 1 | $20 |
| Agios Pharmaceuticals, Inc. | 1 | $19 |
| Corcept Therapeutics | 1 | $19 |
| Exelixis Inc. | 1 | $18 |
| Mylan Specialty L.p. | 1 | $18 |
| Braemar Manufacturing, LLC | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $14 |
| Novartis | 1 | $14 |
| Sumitomo Pharma America, Inc. | 1 | $13 |
| Eisai Inc. | 1 | $12 |
| Merck | 1 | $12 |
How this compares
$2,588 in reported general payments places this provider in the 75th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 183 | $203,651 |
| MounjaroTirzepatide | 151 | $194,735 |
| EliquisApixaban | 109 | $100,803 |
| FarxigaDapagliflozin Propanediol | 88 | $90,809 |
| OzempicSemaglutide | 59 | $66,384 |
| JanuviaSitagliptin Phosphate | 58 | $62,484 |
| XareltoRivaroxaban | 43 | $48,585 |
| RybelsusSemaglutide | 29 | $45,929 |
| GlyxambiEmpagliflozin/Linagliptin | 27 | $40,579 |
| LinzessLinaclotide | 42 | $38,357 |
| MyrbetriqMirabegron | 52 | $35,399 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $34,319 |
| GemtesaVibegron | 27 | $18,374 |
| Rosuvastatin Calcium | 656 | $16,340 |
| Esomeprazole Magnesium | 140 | $12,738 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Glyxambi, Spiriva Respimat | $137 | $250,520223 claims |
| Lilly USA, LLCMounjaro | $134 | $194,735151 claims |
| Novo NordiskOzempic, Rybelsus | $498 | $112,31388 claims |
| PfizerEliquis | $148 | $100,803109 claims |
| AstraZenecaFarxiga | $418 | $90,80988 claims |
| MerckJanuvia | $12 | $62,48458 claims |
| Johnson & JohnsonXarelto | $30 | $48,58543 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $289 | $44,23761 claims |
| AbbVieLinzess, Synthroid | $44 | $43,183104 claims |
| Astellas Pharma US IncMyrbetriq | $20 | $35,39952 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $13 | $18,37427 claims |
| BayerKerendia | $52 | $8,81314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Montgomery
- John PorterMontgomery$316K
- Joel McCloudMontgomery$27K
- John JerniganMontgomery$25K
- Harry StuddardMobile$12.9M
- Almena FreeAnniston$12.7M
- Hayes WilliamsVestavia$10.4M
- David DeatkineBirmingham$8M
- James SullivanBirmingham$6M
- Ramy TomaBirmingham$5.1M
- Barry McLeanHomewood$4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.